Navigating the Changing Landscape of Relapsed/Refractory Multiple Myeloma: Optimizing Treatment Strategies : Episode 3
R/R MM: Bispecifics in R/R MM: Key Takeaways
Panelists discuss how to manage talquetamab-associated adverse events, such as skin toxicities and dysgeusia, sharing their clinical experience with toxicity timing, frequency, and key strategies for fellow oncologists implementing bispecific antibodies in relapsed/refractory multiple myeloma.
EP: 1.R/R MM: Treating Patients with CNS Metastases Involvement
EP: 2.Optimal Dosing Strategies and Managing AEs
Now Viewing
EP: 3.R/R MM: Bispecifics in R/R MM: Key Takeaways
EP: 4.R/R MM: Insights Into Optimal Dosing for Bispecifics
EP: 5.Bispecifics in R/R MM: AE Management and Sequencing
EP: 6.Future Perspectives in R/R MM
EP: 7.R/R MM Treatment Landscape: Role of Bispecifics
EP: 8.Clinical Pearls Surrounding the Use of Bispecifics in R/R MM
Video content above is promoted by the following;
- What are your current strategies for managing AEs (skin toxicities, dysgeusia, etc) seen with talquetamab?
- When do these toxicities typically appear, and how often do you see them in practice?
- Please share your key takeaways from that meeting, especially surrounding the use of bispecifics (dosing, AE management) in R/R MM.
- What clinical pearls can you share for fellow medical oncologists considering the use of bispecifics in R/R MM?
Recent Videos
Related Content
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Article
Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
